- The 50UI, 100UI and 200UI formulations cover aesthetic and therapeutic indications
- The strong partnership with Medica Group will drive Hugel’s expansion in the MENA region
The approval of Botulax in 50 IU, 100 IU and 200 IU covers five aesthetic and medical indications: eyelid spasm; crow’s feet; glabellar lines; muscle spasticity of the upper limbs after a stroke; and adduction deformity due to cerebral palsy in children.
The company plans to officially release Botulax toxin into the
Hugel will accelerate its market expansion through unique sales and marketing strategies in the region. Building on the success of its hyaluronic acid dermal filler Revolax, which gained approval from the
The MENA region represents one of the fastest growing medical aesthetics markets, driven by robust economic growth, favorable demographic trends, increasing social media engagement and increasing demand for aesthetic treatments. Hugel is preparing for the approval process of its toxin in other MENA countries such as
“We are excited about the growth potential in the MENA market with the approval of Botulax with aesthetic and therapeutic indications. Hugel will expand its activities thanks to the high quality of the toxin and Medica Group a comprehensive understanding of the market and its combined active partnerships with regional networks,” said a Hugel official.
About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectable products for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers and skin boosters, as well as as absorbable sutures and cosmetic products. As a market leader in injectable aesthetics in
Contact:
[email protected]